The Effect of Atorvastatin on Endothelial Cell Dysfunction in Chronic Kidney Disease

• Status: Terminated
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if patients with chronic kidney disease have endothelial cells that don't function properly, which is thought to be a marker for cardiovascular risk. Endothelial cells line the heart and blood vessels. The investigators will treat your high cholesterol with a cholesterol-lowering drug (atorvastatin, or Lipitor). They will determine if this cholesterol lowering drug improves subjects' cholesterol as well as the function of endothelial cells.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Duke University
• Treatments: Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• Stage 3, 4 and 5 chronic kidney disease (not on dialysis)

• Hyperlipidemia requiring cholesterol lowering therapy

• Aged 18 to 80 years old

• Ability to provide informed consent

Exclusion Criteria:

• Patients requiring multiple cholesterol reducing agents

• Patients with neovascularization present, such as neoplasm, active wounds, or significant retinopathy

• Patients with contraindications or allergy to statins